Therapeutics, or coming up with the next life-saving drug requires going through vast quantities of data and making various calculated guesses on how the human body will behave, this costs millions and often billions. AI has the potential to help make sense of this data in that it helps to see patterns and the AI will help make smarter predictions on how to deploy resources on research and experiments.
- Access to the most exciting scientific ideas through its live grassroots working relationships in the biotech community for over 20 years.
- Operating from their proprietary 2.7 acre Mill SciTech Park the fund can incubate life science companies leading to more effective decision making.
- The fund is structured to be EIS compliant providing income, inheritance and capital gains tax breaks for UK taxpayers.
Fund Size | Target £ 10m |
---|---|
Tax Advantages | Under new "Approved EIS funds" investor are eligible for added tax advantages. A carry-back rule enable investors to set their relief against income tax liabilities in the year before the fund closes. |
Diversification | Aim to build investors an initial Portfolio of 5-10 unquoted and/or AIM-listed companies. |
Tax Relief | 30% income tax relief * |
For more details on the fund, please download fund documents
For more details on the fund, please download fund documents
EIS tax relief is very attractive for UK tax payers
You invest £50k
EIS gives you £15k tax relief from HMRC
EIS gives you £25k tax relief from HMRC
Investment now worth £100k
£50k profit
income tax relief £15k
performance incentive £10k
net profit £55k
Investment still worth £50k
£0 profit
income tax relief £15k
performance incentive £0
net profit £15k
Investment now worth £0
£50k loss
income tax relief £15k
loss relief £15,750 *
performance incentive £0
capital loss £19,250
* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees
Need help in understanding how investing in EIS works?
Need help in understanding how investing in EIS works?
Subscribe to Get Latest Updates on Our Portfolio Companies
- o2h Ventures Portfolio Company ViaNautis Enters Strategic Collaboration Agreement with Eli Lilly to Accelerate Genetic Medicine Development 30 October, 2024
- o2h Ventures, Third-Time Finalist in the Best EIS Manager Specialist at the Growth Investor Awards 2024 9 August, 2024
- Proud Partner of the 30th Anniversary Event by EISA, celebrating three decades of Enterprise Investment Schemes (EIS) 6 August, 2024